Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E F Smit

Showing results (111-120 of 185) with videos related to

Pageof 19
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|May 30, 2009
A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutationsD Kramer, F B Thunnissen, M I Gallegos-Ruiz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2013
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 studyJ G Aerts, H Codrington, N A G Lankheet, et al.
Immuno-Oncology Technology|August 15, 2022
Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatmentsS M Castenmiller, R de Groot, A Guislain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2023
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
International Journal of Cancer|April 22, 1992
In vitro response of human small-cell lung-cancer cell lines to chemotherapeutic drugs; no correlation with clinical dataE F Smit, E G de Vries, H Timmer-Bosscha, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2023
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
British Journal of Cancer|November 23, 2016
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatmentJ L Kuiper, S M S Hashemi, E Thunnissen, et al.
European Journal of Cancer (Oxford, England : 1990)|September 2, 2015
Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based studyL E Hendriks, J L Derks, P E Postmus, et al.
Pageof 19

Showing results (111-120 of 185) with videos related to

Sort By:
Pageof 19
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 29, 2020
Correction to: "Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up"D Planchard, S Popat, K Kerr, et al.
Cellular Oncology : the Official Journal of the International Society for Cellular Oncology|May 30, 2009
A fast, sensitive and accurate high resolution melting (HRM) technology-based assay to screen for common K-ras mutationsD Kramer, F B Thunnissen, M I Gallegos-Ruiz, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 5, 2018
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upD Planchard, S Popat, K Kerr, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|August 30, 2013
A randomized phase II study comparing erlotinib versus erlotinib with alternating chemotherapy in relapsed non-small-cell lung cancer patients: the NVALT-10 studyJ G Aerts, H Codrington, N A G Lankheet, et al.
Immuno-Oncology Technology|August 15, 2022
Effective generation of tumor-infiltrating lymphocyte products from metastatic non-small-cell lung cancer (NSCLC) lesions irrespective of location and previous treatmentsS M Castenmiller, R de Groot, A Guislain, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 5, 2023
Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
International Journal of Cancer|April 22, 1992
In vitro response of human small-cell lung-cancer cell lines to chemotherapeutic drugs; no correlation with clinical dataE F Smit, E G de Vries, H Timmer-Bosscha, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 20, 2023
Non-oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-upL E Hendriks, K M Kerr, J Menis, et al.
British Journal of Cancer|November 23, 2016
Non-classic EGFR mutations in a cohort of Dutch EGFR-mutated NSCLC patients and outcomes following EGFR-TKI treatmentJ L Kuiper, S M S Hashemi, E Thunnissen, et al.
European Journal of Cancer (Oxford, England : 1990)|September 2, 2015
Single organ metastatic disease and local disease status, prognostic factors for overall survival in stage IV non-small cell lung cancer: Results from a population-based studyL E Hendriks, J L Derks, P E Postmus, et al.
Pageof 19